Current Updates on in vitro Dissolution Testing for Immediate Release Oral Dosage Forms
Mehedi Mala Mitu
International Business, Jenphar Bangladesh Limited, Dhaka, Bangladesh.
Tirtha Nandi *
Alnylam Pharmaceuticals, Cambridge, MA, USA.
*Author to whom correspondence should be addressed.
Abstract
Immediate-release oral dosage forms, also known as IR dosage forms, have become a popular choice for administering medication due to their ability to dissolve at an accelerated rate. This means that the medication is quickly released into the bloodstream, providing fast relief to patients. In the formulation development process, dissolution is a crucial aspect to consider as it can provide valuable information for quality control. In vitro dissolution testing, a laboratory method that simulates the dissolution of medication in the body, can offer insight into various stages of drug development.
From a regulatory perspective, the review of preclinical and clinical data is greatly facilitated by the validation of dissolution for the product. In some cases, it may even be appropriate to use dissolution test results to evaluate the biopharmaceutical implications of a product change. This type of testing helps to ensure that the medication is not only effective, but also safe and reliable for patients.
In vitro dissolution testing can be used to evaluate a variety of factors including the rate of dissolution, the amount of medication released, and the effect of different formulations on dissolution. This can help researchers and manufacturers to optimize the formulation of the medication and ensure that it meets the necessary standards for efficacy and safety.
In conclusion, in vitro dissolution testing is an essential tool for evaluating the quality and performance of immediate-release oral dosage forms. It provides valuable information for the development and regulatory approval of medication, and can help to ensure that patients receive safe and effective treatment.
Keywords: BCS class, in vitro dissolution, FDA, EMA, immediate release dosage forms
How to Cite
References
Nandi T. Importance of sufficient time-points for efficient pharmacokinetic (PK) compartmental modeling. International Journal of Applied Pharmaceutics. 2023; 15(1):87-92.
Ghosh R, Nayan MIH, Mitu MM, Nandi T. Common Approaches of Cytochrome P450 (CYP) Induction Assays. International Blood Research & Reviews. 2023;14(1): 6-14.
Nandi T. Time-dependent inactivation of intestinal cytochrome P450S and its impact on systemic bioavailability; 2022.
Nandi T, Korzekwa K, Nagar S, editors. Inclusion of intestinal metabolism in a continuous intestinal absorption model to predict clinical pharmacokinetics of oral midazolam 2022.
Nyol S, Gupta MJJoDD, Therapeutics. Immediate drug release dosage form: a review. 2013;3(2).
Sharma N, Pahuja S, Sharma NJIJPSR. Immediate release tablets: A review. 2019;11:3607-18.
Neha D, Kamini KM, Neeraj P, Manmohan S, Kamal V, Neeraj SJWJoP, et al. Immediate release tablets: A review. 2017;6(4):595-611.
Rediguieri CF, Porta V, Nunes DS, Nunes TM, Junginger HE, Kopp S, et al. Biowaiver monographs for immediate release solid oral dosage forms: metronidazole. 2011;100(5):1618-27.
Buwade P, Jadiya S, Shukla T, Upmanyu DNJWJoPR. Advantages of immediate release tablets over the other tablet forms. 2015;4(11):757-80.
Rahul M, Patil S, Shetkar M, Chavan D, Bhagwat PJP. A review on immediate release drug delivery systems. 2014; 2(8):95-109.
Perrie Y, Rades T. FASTtrack Pharmaceutics: Drug Delivery and Targeting: Pharmaceutical press; 2012.
Gupta E, Barends D, Yamashita E, Lentz K, Harmsze A, Shah V, et al. Review of global regulations concerning biowaivers for immediate release solid oral dosage forms. 2006;29(3-4):315-24.
GL19 VJCfVM. Guidance for Industry; 2002.
Hermans A, Abend AM, Kesisoglou F, Flanagan T, Cohen MJ, Diaz DA, et al. Approaches for establishing clinically relevant dissolution specifications for immediate release solid oral dosage forms. 2017;19(6):1537-49.
Fortunato DJDT. Dissolution method development for immediate release solid oral dosage forms. 2005;12(3):11.
Bredael GM, Liang S, Hahn DJDT. A strategy for quality control dissolution method development for immediate-release solid oral dosage forms. 2015;22:10-6.
Banakar UV. Pharmaceutical dissolution testing: CRC Press; 1991.
Nandi T, Rahman A, Jahan N, Islam R, Pavel O. Determination of in vitro release kinetics of metformin hydrochloride from six brands of metformin hydrochloride tablets available in Bangladesh using water media: A UV spectroscopic analysis. Spec J Med Res Health Sci. 2017;2(2): 8-16.
Nandi T, Rahman MA, Hossain MK, Pavel OF, Sultana R. In-vitro comparative dissolution study of different brands of Ranitidine hydrochloride tablets available in Bangladesh. International Journal of Sciences and Applied Research. 2016; 3(7):14-20.
Nandi T, Rahman MA, Islam RS, Mozumder SH, Hasan KS, Rahman M, et al. In-vitro release kinetics of clonazepam from five brands of clonazepam available in Bangladesh Using UV Spectroscopic Analysis in Deionized Water Media; 2017.
Nandi T, Rahman MA, Pavel OF, Liza SA, Huq MA, Haque MJ, et al. Impact of Calcium-Vitamin D Supplements on the Dissolution Pattern of Ranitidine Hydrochloride Tablets: An in vitro Dissolution Study using UV Spectroscopy. Journal of Biomedical and Pharmaceutical Research. 2016;5(5):17-21.
Tamanna S, Nandi T, Shahriar R, Barek MA, Zamsad M. In-vitro comparative dissolution study of different brands of levocetirizine dihydrochloride available in Bangladesh. International Journal of Innovation and Applied Studies. 2019; 26(2):556-61.
Lee SL, Raw AS, Yu L. Dissolution testing. Biopharmaceutics applications in drug development: Springer. 2008;47-74.
Anand O, Yu LX, Conner DP, Davit BMJTAj. Dissolution testing for generic drugs: An FDA Perspective. 2011;13(3): 328-35.
Dressman JB, Krämer J. Pharmaceutical dissolution testing: Taylor & Francis Boca Raton, FL; 2005.
Kraemer J, Gajendran J, Guillot A, Schichtel J, Tuereli AJJoP, Pharmacology. Dissolution testing of orally disintegrating tablets. 2012;64(7):911-8.
Storey DEJDIJ. The role of dissolution testing in the design of immediate release dosage forms. 1996;30(4):1039-44.
Dressman JB, Amidon GL, Reppas C, Shah VPJPr. Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms. 1998; 15(1):11-22.
Marroum PJJDT. History and evolution of the dissolution test. 2014;21(3):11-6.
Food, Administration D, Food, Evaluation DAJCfD, Research UDoH, Services H. Guidance for industry: dissolution testing of immediate release solid oral dosage forms; 1997.
Forms IRSODJVDT, Documentation IVB. Scale-Up and Postapproval Changes: Chemistry, Manufacturing, and Controls. 1995;415.
SUPAC-MR FJVDT, . IVBD. Modified Release Solid Oral Dosage Forms: Scale-Up and Post-Approval Changes: Chemistry, Manufacturing, and Controls; 1997.
Verbeeck RK, Musuamba FTJJoP, Sciences P. The revised EMA guideline for the investigation of bioequivalence for immediate release oral formulations with systemic action. 2012;15(3):376-88.
Morais JAG, Lobato MdRJB, pharmacology c, toxicology. The new European Medicines Agency guideline on the investigation of bioequivalence. 2010; 106(3):221-5.
Kanojiya S, Patel N, Patel RJ, Patel AAJIJODRA. Comparison of dissolution profile for immediate-release dosage form for US and Europe. 2022;10(2):35-8.
Davit BM, Kanfer I, Tsang YC, Cardot J-MJTAj. BCS biowaivers: similarities and differences among EMA, FDA, and WHO requirements. 2016;18(3):612-8.
Shah VP, Gurbarg M, Noory A, Dighe S, Skelly JPJJops. Influence of higher rates of agitation on release patterns of immediate‐release drug products. 1992; 81(6):500-3.
Shiu GKJDIJ. Dissolution methodology: apparatus and conditions. 1996;30(4): 1045-54.
Qiu S, Wang K, Li MJDT. In vitro dissolution studies of immediate-release and extended-release formulations using flow-through cell apparatus 4. 2014;21: 6-16.
Guidance FJF, Drug Administration CfDE, Research. Guidance for industry: Dissolution testing of immediate release solid oral dosage forms. US Department of Health and Human Services; 1997.
Hasan MM, Rahman MM, Islam MR, Hasan H, Hasan MM, Rashid HAJTPIJ. A key approach on dissolution of pharmaceutical dosage forms. 2017; 6(9):168-80.
Salve PM, Sonawane SV, Patil MB, Surawase RK. Dissolution and Dissolution Test Apparatus: A Review; 2021.
Yu LX, Wang JT, Hussain ASJAP. Evaluation of USP apparatus 3 for dissolution testing of immediate-release products. 2002;4(1):1-5.
Fotaki N, Brown W, Kochling J, Chokshi H, Miao H, Tang K, et al. Rationale for selection of dissolution media: Three case studies. 2013;20:6-13.
Pharmacopeia UJW, DC. 32-NF-27, the United States Pharmacopeial Convention. 2009;2701.
Fotaki N, Vertzoni MJTODDJ. Biorelevant dissolution methods and their applications in in vitro-in vivo correlations for oral formulations. 2010;4(1).
Saxena S, Jain SJAJoP, Technology. A review on biopharmaceutical classification system. 2019;9(4).
Farah K, Syed MFH, Madiha M, Rabia N, Sana G, Iyad NM, et al. Comparative analysis of biopharmaceutic classification system (BCS) based biowaiver protocols to validate equivalence of a multisource product. 2020;14(7):212-20.
Limberg J, Potthast HJB, disposition d. Regulatory status on the role of in vitro dissolution testing in quality control and biopharmaceutics in Europe. 2013;34(5): 247-53.
Mauger JWJDT. Physicochemical properties of buffers used in simulated biological fluids with potential application for in vitro dissolution testing: A mini-review. 2017;24(3):38-51.
Scott N, Patel K, Sithole T, Xenofontos K, Mohylyuk V, Liu FJIJoP. Regulating the pH of bicarbonate solutions without purging gases: Application to dissolution testing of enteric coated tablets, pellets and microparticles. 2020;585:119562.
Nissankararao S, Kallam V, Bhimavarapu RJIJPRD. Dissolution method development and validation: a review. 2013;5:106-12.
Polli JEJTAj. A Simple One-Parameter Percent Dissolved Versus Time Dissolution Equation that Accommodates Sink and Non-sink Conditions via Drug Solubility and Dissolution Volume. 2023;25(1):1-16.
Balakrishnan A, Rege BD, Amidon GL, Polli JEJJops. Surfactant-mediated dissolution: contributions of solubility enhancement and relatively low micelle diffusivity. 2004;93(8):2064-75.
Park S-H, Choi H-KJIjop. The effects of surfactants on the dissolution profiles of poorly water-soluble acidic drugs. 2006; 321(1-2):35-41.
Ropers M, Czichocki G, Brezesinski GJTJoPCB. Counterion effect on the thermodynamics of micellization of alkyl sulfates. 2003;107(22):5281-8.
Shin ES, Kim K, Oh SH, Cho WIJCc. Polysulfide dissolution control: the common ion effect. 2013;49(20):2004-6.
Gao Z, Moore TW, Doub WH, Westenberger B, Buhse LFJJops. Effects of deaeration methods on dissolution testing in aqueous media: a study using a total dissolved gas pressure meter. 2006;95(7):1606-13.
Qureshi S, McGilveray IJDd, pharmacy i. A critical assessment of the USP dissolution apparatus suitability test criteria. 1995; 21(8):905-24.
Riley T, Christopher D, Arp J, Casazza A, Colombani A, Cooper A, et al. Challenges with developing in vitro dissolution tests for orally inhaled products (OIPs). 2012; 13(3):978-89.
Shohin I, Grebenkin DY, Malashenko E, Stanishevskii YM, Ramenskaya GJDT. A brief review of the FDA dissolution methods database. 2016;23(3):6-10.
Gray VA, Zheng JY, Sesi NNJF, Products ADfL-DOD. In vitro dissolution testing and method development. 2009:265.
Likar MD, Mansour HL, Harwood JWJJop, analysis b. Development and validation of a dissolution test for a once-a-day combination tablet of immediate-release cetirizine dihydrochloride and extended-release pseudoephedrine hydrochloride. 2005;39(3-4):543-51.
Marles RJ, Barrett ML, Barnes J, Chavez ML, Gardiner P, Ko R, et al. United States pharmacopeia safety evaluation of Spirulina. 2011;51(7):593-604.
Dayyih WA, Hamad M, Mallah E, Abu Dayyih A, Awad RJI. METHOD Development and Validation of Vildagliptin and Metformin HCl in Pharmaceutical Dosage form by Reversed Phase-High Performance Liquid Chromatography (RP-HPLC). 2018;9(7):2965-72.
Rambla-Alegre M, Esteve-Romero J, Carda-Broch SJJoCA. Is it really necessary to validate an analytical method or not? That is the Question. 2012; 1232:101-9.
Vaghela B, Kayastha R, Bhatt N, Pathak N, Rathod DJJoaps. Development and validation of dissolution procedures. 2011;Issue:50-6.
Frick A, Möller H, Wirbitzki EJEjop, biopharmaceutics. Biopharmaceutical characterization of oral immediate release drug products. In vitro/in vivo comparison of phenoxymethylpenicillin potassium, glimepiride and levofloxacin. 1998;46(3): 305-11.
Medina JR, Salazar DK, Hurtado M, Cortes AR, Domínguez-Ramírez AMJSPJ. Comparative in vitro dissolution study of carbamazepine immediate-release products using the USP paddles method and the flow-through cell system. 2014;22(2):141-7.
Chan CC, Pearson N, Rebelo‐Cameirao A, Lee YJAMV, Verification IP. Dissolution method validation. 2004;51-66.
Suarez-Sharp S, Cohen M, Kesisoglou F, Abend A, Marroum P, Delvadia P, et al. Applications of clinically relevant dissolution testing: workshop summary report. Springer; 2018.
Hayes S, Dunne A, Smart T, Davis JJJops. Interpretation and optimization of the dissolution specifications for a modified release product with an in vivo–in vitro correlation (IVIVC). 2004;93(3):571-81.
Pepin XJ, Flanagan TR, Holt DJ, Eidelman A, Treacy D, Rowlings CEJMp. Justification of drug product dissolution rate and drug substance particle size specifications based on absorption PBPK modeling for lesinurad immediate release tablets. 2016;13(9):3256-69.
Long M, Chen Y. Dissolution testing of solid products. Developing solid oral dosage forms: Elsevier. 2009;319-40.
Boudreau SP, McElvain JS, Martin LD, Dowling T, Fields SMJPT. Method validation by phase of development. 2004;28(11):54-66.
FDA UJCfDE, Research. Guidance for Industry, Waiver of in vivo bioavailability and bioequivalence studies for immediate release solid oral dosage forms based on a biopharmaceutics classification system; 2000.
Hofer JD, Gray VAJDT. Examination of selection of immediate release dissolution acceptance criteria. 2003; 10(1):16-20.
Bioavailability FJCfDE, Research. bioequivalence studies for orally administered drug products—general considerations: guidance for industry. Rockville: FDA; 2003.
Meredith PAJDS. Generic drugs. 1996; 15(4):233-42.
Kaur P, Jiang X, Duan J, Stier EJTAj. Applications of in vitro–in vivo correlations in generic drug development: case studies. 2015;17(4):1035-9.
Schwartz JBJPJoPS, Technology. SUPAC. 1996;50(2):67.
Sharma P, Ganta S, Garg S. Scale-Up and Postapproval Changes (SUPAC) Regulations: John Wiley & Sons Limited; 2008.
Mendapara VP, Purohit P, Ashara KJIRPT. SUPAC of immediate release solid oral dosage form-eplerenone. 2013;2013(3): 1-7.
Sah H-K, Park S, Yun M-O, Kang S-JJJoPI. Scrutiny Made to SUPAC-IR Dealing with Postapproval Changes in Immediate Release Sold Oral Dosage Forms. 2004;34(1): 57-71.
Waterland NH, Kowtna CCJPPV. Change control and SUPAC. 2003;742-91.
Nvn M. Scale up and postapproval changes (Supac) guidance for industry: A regulatory note; 2017.
Augsburger LL, Hoag SW. Pharmaceutical dosage forms-tablets: CRC Press; 2016.
Karam RJPbDMK. Biowaivers: Criteria and requirements. 2015;1-11.
Faassen F, Vromans HJCp. Biowaivers for oral immediate-release products. 2004; 43(15):1117-26.
Yu LX, Amidon GL, Polli JE, Zhao H, Mehta MU, Conner DP, et al. Biopharmaceutics classification system: the scientific basis for biowaiver extensions. 2002;19(7):921-5.
Van Oudtshoorn JE, García-Arieta A, Santos GML, Crane C, Rodrigues C, Simon C, et al. A survey of the regulatory requirements for BCS-based biowaivers for solid oral dosage forms by participating regulators and organisations of the international generic drug regulators programme. 2018;21:27-37.
Kalantzi L, Reppas C, Dressman J, Amidon G, Junginger H, Midha K, et al. Biowaiver monographs for immediate release solid oral dosage forms: Acetaminophen (paracetamol). 2006; 95(1):4-14.